Ocular Therapeutix, Inc.

Ocular Therapeutix is a commercial-stage biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. The company utilizes its proprietary ELUTYX™ technology, a bioresorbable hydrogel-based formulation, to provide sustained-release drug delivery that aims to replace traditional eye drops and frequent intraocular injections. The company's primary focus is on retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic retinopathy. By providing long-acting therapies, Ocular Therapeutix seeks to improve patient compliance and clinical outcomes while reducing the treatment burden on patients and healthcare providers.